Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PULSE BIOSCIENCES, INC.PLSE · Entity 1151 | Chief Operating Officer | August 31, 2026 | September 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PULSE BIOSCIENCES, INC.
Report date August 31, 2026 · Filed September 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,095 |
Last balance in matching sequence
After 2026-09-01 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-08-31 · Purchase · Acquired 1,024 · Balance 3,094 F1: The shares were purchased during an open trading window under the Company's Insider Trading Policy and in accordance with applicable securities laws. F2: The purchase of fractional shares has been rounded down to the nearest whole number. F3: Represents the weighted average sale price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $48.76 to $48.80 per share. Row 2 · 2026-09-01 · Purchase · Acquired 1,001 · Balance 4,095 F1: The shares were purchased during an open trading window under the Company's Insider Trading Policy and in accordance with applicable securities laws. F2: The purchase of fractional shares has been rounded down to the nearest whole number. F4: Open market purchase transactions made on the same day at the same price through a trade order executed by a broker-dealer. The reporting person has reported on a single line all such transactions that occurred at the reported price. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were purchased during an open trading window under the Company's Insider Trading Policy and in accordance with applicable securities laws.
F2: The purchase of fractional shares has been rounded down to the nearest whole number.
F3: Represents the weighted average sale price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $48.76 to $48.80 per share.
F4: Open market purchase transactions made on the same day at the same price through a trade order executed by a broker-dealer. The reporting person has reported on a single line all such transactions that occurred at the reported price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 2, 2026 23:38 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 1,001 | $49.95 | $49,999.95 |
DisclosureSEC source: 0001437749-26-029545 · rdgdoc.xml · nonDerivative · entry 2 Teplitsky Liane Rae · CIK 0002132552 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,095 F1 · kind: The shares were purchased during an open trading window under the Company's Insider Trading Policy and in accordance with applicable securities laws. F2 · shares: The purchase of fractional shares has been rounded down to the nearest whole number. F4 · price: Open market purchase transactions made on the same day at the same price through a trade order executed by a broker-dealer. The reporting person has reported on a single line all such transactions that occurred at the reported price. F2 · balance_after: The purchase of fractional shares has been rounded down to the nearest whole number. Read SEC document |
| August 31, 2026 Filed Sep 2, 2026 23:38 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 1,024 | $48.80 | $49,971.20 |
DisclosureSEC source: 0001437749-26-029545 · rdgdoc.xml · nonDerivative · entry 1 Teplitsky Liane Rae · CIK 0002132552 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,094 F1 · kind: The shares were purchased during an open trading window under the Company's Insider Trading Policy and in accordance with applicable securities laws. F2 · shares: The purchase of fractional shares has been rounded down to the nearest whole number. F3 · price: Represents the weighted average sale price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $48.76 to $48.80 per share. F2 · balance_after: The purchase of fractional shares has been rounded down to the nearest whole number. Read SEC document |
| August 28, 2026 Filed Aug 28, 2026 19:48 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 1,034 | $48.35 | $49,993.90 |
DisclosureSEC source: 0001437749-26-029233 · rdgdoc.xml · nonDerivative · entry 2 Teplitsky Liane Rae · CIK 0002132552 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,070 F1 · kind: The shares were purchased during an open trading window under the Company's Insider Trading Policy and in accordance with applicable securities laws. F2 · shares: The purchase of fractional shares has been rounded down to the nearest whole number. F3 · price: Open market purchase transactions made on the same day at the same price through a trade order executed by a broker-dealer. The reporting person has reported on a single line all such transactions that occurred at the reported price. F2 · balance_after: The purchase of fractional shares has been rounded down to the nearest whole number. Read SEC document |
| August 26, 2026 Filed Aug 28, 2026 19:48 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 1,036 | $48.24 | $49,971.46 |
DisclosureSEC source: 0001437749-26-029233 · rdgdoc.xml · nonDerivative · entry 1 Teplitsky Liane Rae · CIK 0002132552 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,036 F1 · kind: The shares were purchased during an open trading window under the Company's Insider Trading Policy and in accordance with applicable securities laws. F2 · shares: The purchase of fractional shares has been rounded down to the nearest whole number. F3 · price: Open market purchase transactions made on the same day at the same price through a trade order executed by a broker-dealer. The reporting person has reported on a single line all such transactions that occurred at the reported price. F2 · balance_after: The purchase of fractional shares has been rounded down to the nearest whole number. Read SEC document |
| August 08, 2026 Filed Aug 28, 2026 19:45 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 700,000 | $0.00 Strike: $19.06 | $0.00 |
DisclosureSEC source: 0001437749-26-029231 · rdgdoc.xml · derivative · entry 2 Teplitsky Liane Rae · CIK 0002132552 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 700,000 shares Expires 2036-08-08 F3 · derivative.exercise_date: Two sevenths of the shares subject to the option will vest in equal installments on the first, second, third, and fourth anniversaries of the grant date and the remaining shares subject to the option will vest in equal tranches upon the achievement of three performance-based vesting criteria tied to both the Issuer's market capitalization ranging from $2 billion to $5 billion and GAAP product revenue targets ranging from $100 million to $330 million, in all cases, subject to the Reporting Person's continued service through each vesting milestone. Read SEC document |
| August 08, 2026 Filed Aug 28, 2026 19:45 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantRestricted Stock Units · Derivative | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-029231 · rdgdoc.xml · derivative · entry 1 Teplitsky Liane Rae · CIK 0002132552 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-08-08 F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's common stock. F2 · derivative.exercise_date: The RSUs will vest upon certain performance-based criteria established by the Board of Directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.